Loading...
XNYS
CRL
Market cap9.07bUSD
Dec 05, Last price  
184.31USD
1D
0.15%
1Q
12.39%
Jan 2017
141.91%
IPO
742.37%
Name

Charles River Laboratories International Inc

Chart & Performance

D1W1MN
XNYS:CRL chart
P/E
880.92
P/S
2.24
EPS
0.21
Div Yield, %
Shrs. gr., 5y
0.77%
Rev. gr., 5y
9.09%
Revenues
4.05b
-1.92%
1,122,228,0001,058,385,0001,230,626,0001,343,493,0001,202,551,0001,133,416,0001,142,647,0001,129,530,0001,165,528,0001,297,662,0001,363,302,0001,681,432,0001,857,601,0002,266,096,0002,621,226,0002,923,933,0003,540,160,0003,976,060,0004,129,409,0004,049,989,000
Net income
10m
-97.83%
141,999,000-55,783,000154,406,000-521,843,000114,441,000-336,669,000109,566,00097,295,000102,828,000126,698,000149,313,000154,765,000123,355,000226,373,000252,019,000364,304,000390,982,000486,226,000474,624,00010,297,000
CFO
735m
+7.41%
236,702,000164,370,000284,248,000279,949,000225,044,000169,013,000205,283,000207,900,000207,139,000251,051,000286,358,000298,319,000316,265,000441,140,000480,936,000546,575,000760,799,000619,640,000683,898,000734,577,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
IPO date
Jun 23, 2000
Employees
20,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT